121 related articles for article (PubMed ID: 27181081)
21. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
22. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Nogawa M; Yuasa T; Kimura S; Kuroda J; Segawa H; Sato K; Yokota A; Koizumi M; Maekawa T
Oncol Res; 2005; 15(1):1-9. PubMed ID: 15839301
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
26. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.
Song JX; Ren JY; Chen H
J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011
[TBL] [Abstract][Full Text] [Related]
29. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD
Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin inhibits mast cell degranulation without changing the cytoplasmic Ca2+ level.
Fujimoto M; Oka T; Murata T; Hori M; Ozaki H
Eur J Pharmacol; 2009 Jan; 602(2-3):432-8. PubMed ID: 19059394
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Budman DR; Calabro A
Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
[TBL] [Abstract][Full Text] [Related]
33. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Rachner TD; Göbel A; Thiele S; Rauner M; Benad-Mehner P; Hadji P; Bauer T; Muders MH; Baretton GB; Jakob F; Ebert R; Bornhäuser M; Schem C; Hofbauer LC
Breast Cancer Res; 2014 Feb; 16(1):R20. PubMed ID: 24528599
[TBL] [Abstract][Full Text] [Related]
34. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
[TBL] [Abstract][Full Text] [Related]
35. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
36. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Al-Haidari AA; Syk I; Thorlacius H
Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560
[TBL] [Abstract][Full Text] [Related]
37. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H
Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852
[TBL] [Abstract][Full Text] [Related]
39. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.
Weivoda MM; Hohl RJ
Endocrinology; 2011 Aug; 152(8):3113-22. PubMed ID: 21586555
[TBL] [Abstract][Full Text] [Related]
40. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
